Seminars

Targeted Radiotherapy for Neuroblastoma with MIBG

Mark Dungan — Fri, 02 Apr 2010 10:05:00 GMT

Join us for a Webinar on April 7

Space is limited.
Reserve your Webinar seat now at:
https://www2.gotomeeting.com/register/202269403

Dr. Kate Matthay, New Approaches to Neuroblastoma Therapy (NANT) Consortium leader and pediatric oncologist from the University of California - San Francisco (UCSF) presents part 2 of the ongoing NANT clinical trial series. This presentation is appropriate for parents of children with neuroblastoma, caregivers, and health care professionals. Dr. Matthay will be presenting the latest information concerning the use of MIBG in neuroblastoma therapy. She will discuss previous clinical research in MIBG and what is currently available to patients through clinical trials. You can expect to leave this meeting with a thorough understanding of MIBG treatment in neuroblastoma, the eligibility requirements, and what is currently being offered.

Title:		Targeted Radiotherapy for Neuroblastoma with MIBG

Date:		Wednesday, April 7, 2010

Time:		10:00 AM - 11:00 AM PDT

After registering you will receive a confirmation email containing information about joining the Webinar.

System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP, 2003 Server or 2000

Macintosh®-based attendees
Required: Mac OS® X 10.4.11 (Tiger®) or newer

Overview of NANT Clinical Trials - Part 1

Mark Dungan — Mon, 08 Feb 2010 15:39:00 GMT

This webinar was recorded on February 16,2010 An Update on New Approaches to NeuroblastomaTherapy (NANT) Clinical Trials from Neuroblastoma Foundation on Vimeo . Space is limited. Reserve your Webinar seat now at: https://www2.gotomeeting.com/register...(read more)

An overview of the Phase 1 Trial of TPI-287/Temezolomide in Neuroblastoma and Medulloblastoma

Mark Dungan — Wed, 19 Aug 2009 17:36:00 GMT

This webinar was recorded on August 26, 2009

An overview of TPI 287/Temezolomide in Neuroblastoma from Neuroblastoma Foundation on Vimeo.

Dr. Giselle Sholler, principal investigator and pediatric oncologist from Vermont Cancer Center, will be presenting important information regarding the newly opened "Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma." This presentation is intended for parents and caregivers of children with refractory or recurrent neuroblastoma and medulloblastoma. Dr. Sholler will provide an overview of the preclinical research leading up to the trial. She will also be discussing the rationale behind the trial, the purpose of the study, and the eligibility requirements. Dr. Sholler will share a summary of the treatment plan and delve into some of the patient experiences that have been seen previously. Parents of children that have participated in this trial will also be available to share their experiences. The presentation will be followed with a question and answer session.

Participation in this online seminar will provide you with the information necessary to aid your and your child’s oncologist in deciding whether this trial may or may not be appropriate for your child. Please join us for the hour long presentation and question and answer session on Wednesday, August 26, 2009 at 12:00PM CST.

Title:		An overview of the Phase 1 Trial of TPI 287/Temezolomide in Neuroblastoma and Medulloblastoma

Date:		Wednesday, August 26, 2009

Time:		12:00 PM - 1:00 PM CDT

After registering you will receive a confirmation email containing information about joining the Webinar.

System Requirements
PC-based attendees
Required: Windows® 2000, XP Home, XP Pro, 2003 Server, Vista

Macintosh®-based attendees
Required: Mac OS® X 10.4 (Tiger®) or newer

Space is limited.
Reserve your Webinar seat now at:
https://www2.gotomeeting.com/register/601120458